Bioceltix Income Statement

Financials in millions PLN. Fiscal year is January - December.

Millions PLN. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cost of Revenue	1.79	1.43	1.04	0.7	0.85
Gross Profit	-1.79	-1.43	-1.04	-0.7	-0.85
Selling, General & Admin	15.02	16.36	14.02	8.09	4.81
Other Operating Expenses	-2.47	-3.27	-1.48	-0.29	-1.64
Operating Expenses	13.29	13.66	12.98	8.25	3.55
Operating Income	-15.08	-15.09	-14.02	-8.95	-4.4
Interest Expense	-0.19	-0.17	-0.03	-0.03	-0.02
Interest & Investment Income	0.48	0.42	0.28	-	0.01
Currency Exchange Gain (Loss)	-0.09	-0.09	0.08	-0.04	-0
EBT Excluding Unusual Items	-14.86	-14.92	-13.69	-9.02	-4.42
Gain (Loss) on Sale of Assets	0.02	0.05	-	0.05	0.07
Pretax Income	-14.84	-14.87	-13.69	-8.97	-4.36
Income Tax Expense	-0.05	0.03	-0.01	-0.05	0.04
Net Income	-14.79	-14.9	-13.69	-8.92	-4.4
Net Income to Common	-14.79	-14.9	-13.69	-8.92	-4.4
Shares Outstanding (Basic)	-	5	4	3	3
Shares Outstanding (Diluted)	-	5	4	3	3
Shares Change (YoY)	-	15.76%	17.48%	5.54%	-
EPS (Basic)	-	-3.28	-3.49	-2.67	-1.39
EPS (Diluted)	-	-3.28	-3.49	-2.67	-1.39
Free Cash Flow	-13.13	-17.81	-15.21	-8.23	-4.02
Free Cash Flow Per Share	-	-3.93	-3.88	-2.47	-1.27
EBITDA	-14.35	-14.51	-13.58	-8.51	-4.03
D&A For EBITDA	0.73	0.57	0.43	0.45	0.38
EBIT	-15.08	-15.09	-14.02	-8.95	-4.4

Source: S&P Capital IQ. Standard template. Financial Sources.